Physician profile
John A Zelisko
NPI 1124087168
$506.03
in general payments reported to CMS, 2019-2025
12 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.56 · 2023: $103 · 2024: $204 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $114.75 | 2023-2025 | Calquence |
| Janssen Biotech, INC. | $63.90 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Karyopharm Therapeutics INC. | $58.66 | 2024-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $43.60 | 2024 | Keytruda |
| Legend Biotech USA INC. | $34.82 | 2025 | Carvykti |
| Novartis Pharmaceuticals Corporation | $31.71 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.00 | 2025 | |
| Abbvie INC. | $28.68 | 2024 | |
| Boston Scientific Corporation | $26.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.82 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $24.53 | 2024 | |
| Glaukos Corporation | $22.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zelisko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.